Bachelor of Science

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Retrieved on: 
Tuesday, April 2, 2024
Independent, Business school, Bachelor of Science, Engineering, Bristol Myers Squibb, Thayer School of Engineering, Immunology, Therapy, Corporate development, Corporation, True north, ICON PLC, Business, Dartmouth College, Biogen, ATP, Genzyme, Cardiology, Biomedical engineering, Novo Nordisk, Drug discovery, Tuck School of Business, Acquisition, University, MBBS, AbbVie, Bioverativ, ICON, CBO, Columbia University, Biology, MBA, Hidradenitis suppurativa, TRML, Partner, Military, Management

The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.

Key Points: 
  • The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.
  • The recent board appointments include Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors.
  • He has spent over a decade specializing in founding, building and investing in biotech companies.
  • Samantha also chairs the Board of Advisors for Thayer School of Engineering at Dartmouth and is a member of the Board of Advisors for Life Science Cares.

Seek Labs Welcomes Esteemed Diagnostics Industry Innovator and Executive, Dr. Randy Rasmussen, PhD, to Board of Directors

Retrieved on: 
Friday, March 29, 2024
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, Diagnosis, Growth, Infection, JPMorgan Chase, Knowledge, Bachelor of Science, Sale, Acquisition, University, IPO, Doctor of Philosophy, Utah State University, Molecular biology, Publication, CRISPR, Management

Having amassed a remarkable track record of advancements in molecular diagnostic technologies throughout his career, Dr. Rasmussen is a highly regarded figure in the field of molecular diagnostics.

Key Points: 
  • Having amassed a remarkable track record of advancements in molecular diagnostic technologies throughout his career, Dr. Rasmussen is a highly regarded figure in the field of molecular diagnostics.
  • "We are delighted to welcome Randy Rasmussen to Seek Labs’ Board of Directors," said Jared Bauer, CEO.
  • Dr. Rasmussen expressed his excitement to join Seek Labs’ Board and contribute to the company’s success: “Seek Labs’ commitment to molecular diagnostic innovation aligns with my own passion for diagnostic innovation and improving healthcare outcomes.
  • Dr. Rasmussen currently serves as Chairman of the Board for BioUtah and as a Board Member for Quansys Biosciences.

Rasmussen University Centralizes Ocala Operations into One Location, Begins Classes in Newly Expanded Campus

Retrieved on: 
Thursday, April 4, 2024
Online, Environment, Associate, Education, Simulation, University, Rasmussen University, Physical therapy, Student, Bachelor, Bachelor of Science, Nursing, School

OCALA, Fla., April 4, 2024 /PRNewswire/ -- Rasmussen University today announced the completion of its campus consolidation and centralization efforts in Ocala, which includes an expansion to its campus located at 1227 SW 17th Avenue.

Key Points: 
  • Last fall, Rasmussen announced plans to consolidate its Main and School of Nursing campus operations into a single location, specifically at its nursing campus location, while also expanding the footprint of the nursing campus.
  • Rasmussen began its Spring Quarter this week under one roof at what is now known as the Rasmussen University Ocala campus .
  • "We are thrilled to welcome students, particularly our radiologic technology and medical assisting students, as they join our nursing students at our newly expanded Ocala campus," said Pete Beasley, senior campus executive director, Rasmussen University—Ocala campus.
  • For more information about the Rasmussen University Ocala campus, please visit https://www.rasmussen.edu/locations/florida/ocala/ .

Alexion Canada Appoints Karen Heim as New General Manager

Retrieved on: 
Tuesday, April 2, 2024
Circulatory system, Neurology, AstraZeneca, GSK plc, Metabolism, Hematology, Cardiology, Patient, DSM-IV codes, Research, Alexion Pharmaceuticals, Bachelor of Science, Acquisition, University, Senior, Metallurgy, Nephrology, Queen's University, Rare disease, Immunity (medical), Alexion, Ophthalmology, Pharmaceutical industry

MISSISSAUGA, ON, April 2, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.

Key Points: 
  • MISSISSAUGA, ON, April 2, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.
  • In this role, Ms. Heim will lead the Canadian affiliate in its unwavering commitment to helping people affected by rare diseases live longer, healthier lives.
  • "Karen's deep healthcare experience and incredible passion make her the perfect fit to lead this mission in Canada and drive it with expertise and ambition."
  • "Taking on this leadership role at Alexion Canada as it continues to grow, with a focus on research and innovation, is incredibly exciting," says Ms. Heim.

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
Thursday, March 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

Former KPMG Chairman and CEO Lynne Doughtie Assumes Role as Chair of LUNGevity's Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Lung cancer, NAF (non-profit organization), Glassdoor, KPMG, Organization, Woman, Virginia Tech, Environment, Disease, Boeing, Research, Top, Quality of life, Bachelor of Science, National Association, Estate (law), Management

WASHINGTON, March 21, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, announced today the appointment of Lynne Doughtie, former KPMG chairman and CEO, as chair of its Board of Directors. Doughtie, who has served as a dedicated member of the LUNGevity Board since 2016, brings a wealth of experience and personal commitment to LUNGevity's mission.

Key Points: 
  • WASHINGTON, March 21, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, announced today the appointment of Lynne Doughtie, former KPMG chairman and CEO, as chair of its Board of Directors.
  • Doughtie, who has served as a dedicated member of the LUNGevity Board since 2016, brings a wealth of experience and personal commitment to LUNGevity's mission.
  • In 2015, she became the first woman to be elected chairman and CEO of KPMG, where she spearheaded the firm's growth and innovation, leading a team of over 29,000 professionals.
  • "We are thrilled to welcome Lynne as chair of our Board of Directors," said Andrea Ferris, president and CEO of LUNGevity Foundation.

Avant Technologies Promotes Danny Rittman to Chief Information Officer

Retrieved on: 
Thursday, March 14, 2024
Master's degree, CIO, Intel, Machine learning, Automation, Growth, Computer science, Colorado Technical University, MIT, Qualcomm, Knowledge, CISO, Health care, Bachelor of Science, University, Software, Doctor of Philosophy, IBM, Computer security, Institute of technology, Rittman, Ohio, Stanford University, OTCQB, CAD, La Salle University, Medical device

LAS VEGAS, March 14, 2024 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an artificial intelligence technology (AI) company specializing in developing innovative and advanced AI infrastructure solutions, announces the promotion of Danny Rittman to Chief Information Officer (CIO).

Key Points: 
  • LAS VEGAS, March 14, 2024 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an artificial intelligence technology (AI) company specializing in developing innovative and advanced AI infrastructure solutions, announces the promotion of Danny Rittman to Chief Information Officer (CIO).
  • Rittman, who previously served as Avant's Chief Technology Officer (CTO) and later its Chief Information Security Officer (CISO), has successfully leveraged his extensive and diverse background to support the company's growth and evolution in AI development, infrastructure, management, security, and enterprise architecture.
  • Rittman expressed his excitement about his new role, stating, "I am honored to take on the responsibilities of Chief Information Officer at Avant Technologies.
  • "We are extremely pleased to have Danny step into the CIO role here at Avant," said Timothy Lantz, CEO of Avant Technologies.

Enhancing Prostate Cancer Screening: AI, Imaging and Clinical Innovations, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, Algorithm, MRI, Prostate cancer, Radiology, Medical imaging, Magnetic resonance imaging, Partnership, Prostate-specific antigen, PET, Bachelor of Science, Artificial intelligence, AI, Doctor of Philosophy, MBBS, University College London, Workforce, PSA

TORONTO, March 13, 2024 /PRNewswire-PRWeb/ -- This webinar will delve into how prostate cancer screening has been performed to date and the latest clinical research evaluating new diagnostic tests. The featured speakers will also discuss the critical role artificial intelligence (AI) will play in combination with clinical and imaging tests to deliver sustainable, patient-centric screening pathways.

Key Points: 
  • In this free webinar, learn about the evolution of prostate cancer screening and the shift to magnetic resonance imaging (MRI)-based diagnostic tools for more accurate screening.
  • The featured speakers will share insights into the development of AI-based algorithms in prostate cancer, including best practices and pitfalls.
  • The speakers will also discuss ongoing clinical studies shaping the future of prostate cancer detection and treatment.
  • TORONTO, March 13, 2024 /PRNewswire-PRWeb/ -- This webinar will delve into how prostate cancer screening has been performed to date and the latest clinical research evaluating new diagnostic tests.

Appointment of Chief Financial Officer

Retrieved on: 
Wednesday, March 13, 2024
CFO, Acquisition, Bachelor of Science, HBOS, Management accounting, University, Lloyds Banking Group, Bank, MBA, Account, Customer, LTIP, Management, Barclays, Head

In 2023, following the acquisition of Kensington Mortgages by Barclays, Marc was appointed as Managing Director, CFO of Kensington Mortgages.

Key Points: 
  • In 2023, following the acquisition of Kensington Mortgages by Barclays, Marc was appointed as Managing Director, CFO of Kensington Mortgages.
  • Marc has a BSc in Management Studies from the University of Manchester and an MBA from the University of London.
  • Marc Page will be required to accumulate a shareholding equivalent of 200% of salary over five years.
  • Further details will be disclosed in the Directors’ Remuneration Report within the Company’s Annual Report and Accounts as appropriate.

Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase of Growth

Retrieved on: 
Monday, March 11, 2024
Gilead Sciences, Chemistry, Mantra, Sale, IPO, Doctor of Philosophy, University, Therapy, Business, Organization, Novartis, Bachelor of Science, Science, Biogen, Management

LEXINGTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Hyku Biosciences, Inc. (Hyku), a covalent precision medicine company, today announced the appointment of Kleem Chaudhary, Ph.D. as President and Chief Executive Officer, succeeding co-founder and acting CEO Milind Deshpande, Ph.D. who will now serve as an advisor to the company. Dr Chaudhary will also serve as a member of the Board of Directors of Hyku.

Key Points: 
  • Dr Chaudhary will also serve as a member of the Board of Directors of Hyku.
  • Most recently, he was Chief Operating and Business Officer at Redona Therapeutics.
  • Dr. Chaudhary holds a Ph.D. in chemistry from the University of North Carolina at Chapel Hill and a B.Sc.
  • “We are excited to have Kleem join Hyku and I look forward to working with him to advance the exciting science at Hyku.”